Efficacy of erenumab and factors predicting response after 3 months in treatment resistant chronic migraine: a clinical service evaluation

Treatment with the monoclonal calcitonin gene‐related peptide receptor antibody erenumab: A real‐life study

(2021) Simone de Vries Lentsch et al.   EUROPEAN JOURNAL OF NEUROLOGY

Safety and tolerability evaluation of erenumab for the preventive treatment of migraine

(2021) Christina I. Deligianni et al.   Expert Opinion On Drug Safety

Long‐term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high‐frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study

(2021) Piero Barbanti et al.   HEADACHE

The evolving understanding of risk with calcitonin gene‐related peptide monoclonal antibodies based on real‐world data: A focus on hypertension and Raynaud phenomenon

(2021) Ilana D. Breen et al.   HEADACHE

Predictors of response to erenumab after 12 months of treatment

(2021) Carlo Baraldi et al.   Brain and Behavior

Risk of hypertension in erenumab‐treated patients with migraine: Analyses of clinical trial and postmarketing data

(2021) David W. Dodick et al.   HEADACHE

Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy

(2020) Raffaele Ornello et al.   JOURNAL OF HEADACHE AND PAIN

The socioeconomic burden of migraine: An evaluation of productivity losses due to migraine headaches based on a population study in Germany

(2020) Ahmed H Seddik et al.   CEPHALALGIA

A prospective real-world analysis of erenumab in refractory chronic migraine

(2020) Giorgio Lambru et al.   JOURNAL OF HEADACHE AND PAIN

Real-world effectiveness and tolerability of erenumab: A retrospective cohort study

(2020) Saad Kanaan et al.   CEPHALALGIA

Erenumab in Chronic Migraine: An Australian Experience

(2020) Shuli Cheng et al.   HEADACHE

Real‐World Patient Experience With Erenumab for the Preventive Treatment of Migraine

(2020) Jennifer Robblee et al.   HEADACHE

Erenumab in the prevention of high‐frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real‐life study

(2020) Piero Barbanti et al.   HEADACHE

The appropriate dosing of erenumab for migraine prevention after multiple preventive treatment failures: a critical appraisal

(2019) Raffaele Ornello et al.   JOURNAL OF HEADACHE AND PAIN

Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study

(2018) Messoud Ashina et al.   CEPHALALGIA

ARISE: A Phase 3 randomized trial of erenumab for episodic migraine

(2018) David W Dodick et al.   CEPHALALGIA

Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition

(2018)   CEPHALALGIA

Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study

(2018) Uwe Reuter et al.   LANCET

Blocking CGRP in migraine patients – a review of pros and cons

(2017) Marie Deen et al.   JOURNAL OF HEADACHE AND PAIN

Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial

(2017) Stewart Tepper et al.   LANCET NEUROLOGY

A Controlled Trial of Erenumab for Episodic Migraine

(2017) Peter J. Goadsby et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pathophysiology of Migraine: A Disorder of Sensory Processing

(2017) Peter J. Goadsby et al.   PHYSIOLOGICAL REVIEWS